Skip to main content
. 2018 Oct 30;91(18):e1660–e1668. doi: 10.1212/WNL.0000000000006423

Table 3.

Improvements in patient-reported and clinical outcomes from baseline to week 48; disease progression, confirmed relapses, and new MRI disease activity from baseline to week 48

graphic file with name NEUROLOGY2017853101TT3.jpg